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1146Objectives: Preoperative comorbidities (PCMs) are known risk factors for Norwood stage I (NW1). We tested
the hypothesis that short-term bilateral pulmonary arterial banding (bPAB) before NW1 could improve the
prognosis of these high-risk patients.
Methods: From January 2006 to October 2011, 17 high-risk patients with hypoplastic left heart syndrome
(defined as having 4 of the following PCMs: prolonged mechanical ventilation; older age; sepsis; necrotizing
enterocolitis; hepatic, renal, or heart failure; coagulopathy; pulmonary edema; high inotropic requirements;
anasarca; weight<2.5 kg; and cardiac arrest) were identified. In addition to conventional treatment of PCMs,
they underwent bPAB before NW1. bPAB was undertaken with Silastic slings and secured with ligaclips to a
luminal diameter of approximately 3.5 to 4.0 mm. The patency of the ductus arteriosus was maintained with
prostaglandin. NW1 was performed using a modified, right Blalock-Taussig shunt at a median interval of 8
days after bPAB. The data from these patients were retrospectively reviewed, and the 30-day mortality and
1-year survival were compared with the hypoplastic left heart syndrome population who underwent primary
NW1 with<3 PCMs in the same period.
Results: Of the bPAB patients, 5 (29.4%) died before NW1. All had 5 PCMs. Twelve patients (70.6%)
survived to undergo NW1. One early death occurred after NW1 (8.3%). The 1-year survival rate for
high-risk patients who underwent NW1 was 66.7%. The early mortality and 1-year survival for the 130 patients
with<3 PCMs was 10% and 80%, respectively.
Conclusions: Optimizing the balance between the pulmonary and systemic blood flow with a short period of
bPAB and ductal patency can improve the perioperative conditions of high-risk patients before NW1. Those
who survived bPAB and underwent NW1 had early mortality and 1-year survival comparable to the standard
risk category, despite the severity of their initial condition. A rapid 2-stage NW1 strategy with bPAB and
prostaglandin to maintain ductal patency can avoid the risks of suboptimal palliation and vascular injuries
associated with hybrid procedures. (J Thorac Cardiovasc Surg 2013;146:1146-52)The surgical outcomes for hypoplastic left heart syndrome
(HLHS) and related variants have progressively improved
during the past years, owing to a better understanding of
the pathophysiology and improvement in perioperative
management. Different surgical strategies have been
proposed, including Norwood stage I (NW1), a hybrid
procedure, and heart transplantation. NW1 with either a
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However, a subset of patients remains whose mortality
and morbidity remain elevated because of very poor
preoperative conditions.1-3
Because of the referral pattern of our practice, we have
been treating a number of high-risk patients, often coming
from outside the United Kingdom, older than the usual
population with HLHS, and frequently with several
PCMs. Some of the PCMs were inherent to the patient
(chromosomal abnormalities, prematurity, low weight,
age), others were directly related to the prolonged high
pulmonary recirculation and systemic hypotension, sepsis,
and subsequent inadequate end-organ perfusion (renal
failure, hepatic failure, necrotizing enterocolitis, prolonged
mechanical ventilation, high inotropic requirements).
To lower the operative risk of these patients before the
NW1 operation, some centers have adopted a hybrid
strategy, with bilateral pulmonary arterial banding (bPAB)
andpatent ductus arteriosus stenting.However, recent studies
have suggested that the hybrid procedure results in poorer
physiologic palliation than surgical NW1.4 We adopted agery c November 2013
Abbreviations and Acronyms
bPAB ¼ bilateral pulmonary arterial banding
HLHS ¼ hypoplastic left heart syndrome
NW1 ¼ Norwood stage I
Qp/Qs ¼ pulmonary/systemic flow ratio
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stable patient group. The procedure consisted of bPAB asso-
ciated with prostaglandin infusion to maintain the patency of
the ductus arteriosus to rebalance the pulmonary/systemic
flow ratio (Qp/Qs) and improve end-organ perfusion. Once
the patient had improved clinically, with normalization of he-
patic and renal function, we performed early NW1. This
strategy, which differs from the hybrid approach, offers an
alternative approach for severely ill patients, with no impor-
tant pulmonary arterial complications associated with bPAB,
no significant pericardial adhesions, undisturbed integrity of
the aortic arch with antegrade cerebral perfusion, and poten-
tially better cerebral and systemic oxygen delivery.5
We have reported our experience with the rapid 2-stage
Norwood strategy for these high-risk patients and compared
the outcomes with those of low-risk patients undergoing
NW1 during the same period.
METHODS
Patient Inclusion Criteria
From January 2006 to October 2011, 147 patients presentedwith HLHS.
Of these patients, 17 patients with high-riskHLHS or variant underwent the
rapid 2-stage Norwood strategy. These high-risk patients were defined as
having 4 of the following PCMs: age >2 weeks, weight <2.5 kg,
prolonged mechanical ventilation (>2 weeks), systemic sepsis, necrotizing
enterocolitis, heart, renal or hepatic failure, coagulopathy, pulmonary
edema, sustained hypotension, significant inotropic requirements
(adrenaline and/or noradrenaline >0.1 mg/kg/min and/or dopamine
>10.0 mg/kg/min), generalized edema (anasarca), and previous cardiac
arrest. During the same period, 130 patients with standard-risk HLHS
with<3 PCMs underwent the primary NW1 procedure.
The clinical perioperative and outcomes data were obtained from the
patients’ medical records. The patient characteristics, including the
diagnoses and risk factors, are listed in Tables 1 and 2. The study was
registered as an audit/quality improvement project at Great Ormond
Street Hospital, and, as such, the need for full ethical approval was waived.
bPAB Procedure
The bPAB procedure was performed through a median sternotomy and
partial pericardiotomy. With minimal dissection, bPAB was performed
sequentially using Silastic slings around the arteries. The size of the
PAB was calibrated using a right-angled Dennis-Brown dissector
(external diameter of approximately 4.0 mm) and secured with ligaclips
(Figure 1). The degree of constriction was considered adequate with an
arterial oxygen saturation of 75% to 85% using pulse oximetry, and
this was usually associated with the elevation of the systemic arterial
systolic and diastolic blood pressure. The patency of both pulmonary
arteries was checked postoperatively by serial transthoracic echocardio-
grams. The patency of the ductus arteriosus was maintained by
continuous intravenous infusion of prostaglandin E1. After bPAB, all
patients stayed in the cardiac intensive care unit and remainedThe Journal of Thoracic and Carmechanically ventilated, with supportive management of the PCMs. In-
terval NW1 was undertaken when the only remaining PCMs were older
age, low weight, and previous cardiac arrest.
NW1 Operation
The surgical procedure consisted of a NW1 with division of the ductus
arteriosus, division of the main pulmonary artery and side-to-side
anastomosis with the ascending aorta, aortic arch augmentation, and
reconstruction using a pulmonary homograft and atrial septectomy.
Pulmonary blood flow was established with a 3.0- or 3.5-mm, right,
modified Blalock-Taussig shunt or right ventricle to pulmonary artery
conduit (10% of the patients), according to surgeon preference. Deep
hypothermic circulatory arrest at 18C was used for arch reconstruction.
Follow-up
The outcomes were obtained from most recent medical visits and from
direct correspondence with the referring cardiologist. The follow-up data
were complete. The mean follow-up period was 2.66  1.4 years for the
bPAB group and 2.9  1.6 years for the low-risk category.
Statistical Analysis
The data from 147 patients were retrospectively reviewed. The early
mortality (30 days) and 1-year actuarial survival of the patients who had
undergone NW1 were compared in the 2 groups. Log-rank analysis was
used to compare the actuarial survival of the bPAB and low-risk groups,
and the results are illustrated as Kaplan-Meier survival curves (Figure 2).RESULTS
Patients
In the high-risk groupwere 17 patients (76.5%male), with
a weight range of 1.5 to 4.2 kg (median, 3.0). Their median
age at bPABwas 25 days (range, 13-43). Themedian number
of PCMs before bPABwas 7 (range, 5-9). Of the 17 patients,
1 had 4 PCMs and 16 had5 (Table 2). In addition, 2 patients
were premature, and 2 had chromosomal abnormalities.
Three patients had major extracardiac anomalies; one had
major hepatic malformation, and the others had craniofacial
abnormalities.
The standard risk group included 130 patients (63.9%
male), with a weight range of 1.9 to 3.8 kg (median, 3.1).
The median age at NW1 was 4 days (range, 1-87). The
median number of PCMs before the NW1 was 2 (range, 1-
3). Also, 5 patients were premature, and 5 had chromosomal
abnormalities.Genetic abnormalitieswere detected in the clin-
ical assessment by the pediatric cardiologists, based on well-
known morphologic abnormalities and associated factors.Rapid Two-Stage Norwood
In the high-risk group, all 17 patients underwent initial
bPAB. The velocity flow across the banded pulmonary
arteries was an average of 3.0 to 3.5 m/s. This was achieved
in all patients but 1, in whom the bPAB had to be tightened
4 days after the original operation. In addition, after
bPAB, 3 patients underwent balloon atrial septostomy and
1 patient underwent surgical atrial septectomy because of
a restrictive atrial septal defect.diovascular Surgery c Volume 146, Number 5 1147
TABLE 1. Patient characteristics
Pt. no. Gender Weight at bPAB (kg) Diagnosis Age at bPAB (d)
1 M 4.2 MA, AA 25
2 M 2.4 MA, AA, IAA 33
3 M 2.7 MS, AS, HAA 25
4 F 3 MA, AA 17
5 F 3 MA, AA 34
6 M 3 MA, AA, no RSVC, TAPVC through LSVC on CS 41
7 M 3.7 MA, DORV, IAA 20
8 M 3 LAIso, DORV, AA, common AVV 39
9 M 2.7 DORV, HAA, MA 13
10 M 2.45 MA, HAA, CoAo 43
11 M 3.4 MA, AA 29
12 F 3.3 MA, AA, HAA (severe), TV regurgitation (severe) 29
13 M 3.8 MA, AA, HAA 21
14 M 1.5 MA, AA, HAA 26
15 M 3 MA, AA 23
16 F 3.4 MA, AA, CoAo 15
17 M 2.4 MS, AS, CoAo 22
Pt. no., Patient number; bPAB, bilateral pulmonary artery banding; M, male; MA, mitral atresia; AA, aortic atresia; IAA, interrupted aortic arch; MS, mitral stenosis; AS, aortic
stenosis; HAA, hypoplastic aortic arch; F, female; RSVC, right superior vena cava; TAPVC, total anomalous pulmonary venous connection; LSVC, left superior vena cava;
CS, coronary sinus; DORV, double outlet right ventricle; LAIso, left atrial isomerism; CoAo, coarctation of the aorta; TV, tricuspid valve; AVV, atrioventricular valve.
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ing NW1. In these patients, the median number of PCMs
before bPAB was 7 and had remained unchanged or had
increased after bPAB (Table 2). Of these 5 patients, 3 died
of severe sepsis and multiorgan failure, 1 died of a noncar-
diac pathologic entity (complex congenital hepatic malfor-
mation), 1 patient, with restrictive atrial septal defect, died
soon after balloon atrial septostomy, of no identifiable cause.
Of the 17 patients, 12 (70.6%) showed improvement
after bPAB and underwent a NW1 procedure. The median
number of PCMs before bPAB was 6. The interval betweenTABLE 2. Number of preoperative comorbidities before and after
bPAB
Pt. no.
PCMs before
bPAB (n)
PCMs after
bPAB (n) Outcome
1 7 10 Died before NW1
2 4 2 Alive, TCPC completed
3 5 6 Died before NW1
4 6 2 Died after NW1
5 9 9 Died before NW1
6 6 2 Alive, Glenn completed
7 5 2 Alive, Glenn completed
8 8 2 Died after Glenn
9 4 2 Died after NW1
10 5 2 Alive, Glenn completed
11 6 6 Died before NW1
12 6 3 Died after NW1
13 8 8 Died before NW1
14 9 3 Alive, awaiting Glenn
15 9 3 Alive, awaiting Glenn
16 5 2 Alive, TCPC completed
17 6 2 Alive, TCPC completed
bPAB, Bilateral pulmonary artery banding; Pt. no., patient number; PCMs, preoper-
ative comorbidities; NW1, Norwood stage I; TCPC, total cavopulmonary connection.
1148 The Journal of Thoracic and Cardiovascular SurbPAB and NW1 depended on the time needed for clinical
improvement, when the remaining PCMs were older age,
low weight, and previous cardiac arrest. The median
interval in this cohort was 8 days (range, 3-68).
The median age at NW1 was 38 days (range, 18-96). One
early death (8.3%) occurred, in a patient with a dysplastic
tricuspid valve and severe regurgitation. Three patients
died between 30 days and 1 year after NW1 (25%). Two
of them died before the stage 2 operation (one of bronchial
aspiration and another of acute cardiovascular collapse).
The third patient died of a ruptured basilar artery aneurysm
1 month after the bidirectional Glenn operation.
Of the 8 surviving patients, 2 were awaiting stage 2
operations, 3 had undergone a bidirectional Glenn opera-
tion, and 3 had had completion of the total cavopulmonary
connection at the end of the present study. The 1-year
actuarial survival for these patients was 66.7%.
In the standard risk group who underwent primary NW1,
the early mortality was 10% and the 1-year actuarial
survival was 80%. After the NW1 operation, no statistically
significant difference (P ¼ .277) was found in early
mortality and 1-year survival between those who had
undergone initial bPAB and primary NW1 (Figure 2).
However, the overall mortality in the high-risk group who
underwent initial bPAB was 52.9% at 1 year.
DISCUSSION
Since the original description of NW1 in 1983,6 some
modifications have been proposed regarding the type of
shunt to use or aortic arch reconstruction to perform;
however, the principles of NW1 remain the same. Surgery
is normally undertaken in the first week of life, and the
results of the NW1 have improved over the years becausegery c November 2013
FIGURE 1. Bilateral pulmonary artery banding technique.
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better understanding of the perioperative physiology. Non-
modifiable risk factors have been identified, such as age,
weight, chromosomal abnormalities, and a small aorta.
However, the mortality and morbidity in high-risk patients
with circulatory shock has remained markedly elevated,
and alternative therapeutic strategies have been suggested.
Lang and Norwood7 reported pulmonary artery banding
to limit the pulmonary artery blood flow as a part of theFIGURE 2. Kaplan-Meier curve of actuarial survival after Norwood stage
I operation for patients in the standard risk group (no bilateral pulmonary
artery banding [non-bPAB]) and patients in the high-risk group treated with
bPAB before Norwood stage I. Std.Error, Standard error; CI, confidence
interval; HLHS, hypoplastic left heart syndrome.
The Journal of Thoracic and Carpalliation. In 1993, Gibbs and colleagues8 described the
hybrid procedure, and, progressively, several centers have
been using it as an alternative or procedure of choice
for the treatment of HLHS, especially in high-risk pa-
tients.9-12 This treatment consists of bilaterally banding
the pulmonary arteries and maintaining the patency of the
ductus arteriosus using a metal stent. In these patients,
the subsequent procedure consists of reconstruction of
the aortic arch associated with a bidirectional Glenn
operation, commonly known as comprehensive stage II, at
3 to 6 months of age.
Because of the referral pattern of our practice in treating a
high proportion of late referrals, we have been treating pa-
tients in poor condition, including multiorgan dysfunction
and sepsis. We report our experience using the alternative
strategy of the 2-stage Norwood procedure in that group
of patients. First reported in 2003,13,14 this strategy
consisted of performing bPAB and maintaining the
patency of the ductus arteriosus with prostaglandin E1,
followed by a NW1 operation when the patient was in a
more stable condition. The term ‘‘rapid 2-stage Norwood’’
was previously used in a case report by Schmitz and
Breuer15 in 2008 to describe this approach.
The basic difference between the rapid 2-stage Norwood
I and the hybrid procedure is that the latter is followed by
the comprehensive stage II operation and aortic arch
reconstruction, and the rapid 2-stage is used as a bridge to
improve the clinical status and perform the classic
NW1.16-19 Because the interval between bPAB and NW1
was short, the patency of the ductus arteriosus was
maintained pharmacologically, avoiding the inflammatory
and vascular injuries caused by the stent hardware.20 This
strategy offers an alternative approach for severely ill
patients, with no important issues related to pulmonary
arterial stenosis, no significant pericardial adhesions
resulting, and undisturbed integrity of the aortic arch.
Different techniques of bPAB have been reported.21,22 In
2010, Kitahori and colleagues23 described a scientific
approach to guide the degree of branch PA constriction,
using a 2-mm-wide Gore-Tex strip (W. L. Gore, Flagstaff,
Ariz). The bPAB size was determined from the body weight
plus 1 mm for the left and 1.5 mm for the right pulmonary
artery to achieve an arterial oxygen saturation in the 70s and
echocardiographic velocities of 3.0 to 3.3 m/s.
In practice, however, these very sick and edematous
patients exhibit multiorgan dysfunction and often have
labile systemic and pulmonary vascular resistance that
can change in the postoperative period, after the mechanical
adjustment of the Qp/Qs. Furthermore, the pulmonary
arteries must be banded sequentially, making it more
difficult to optimize the blood flow to each lung at the
surgery. Therefore, the physiologic measurements (sys-
temic blood pressure, arterial oxygen saturation, end-tidal
carbon dioxide) that are done intraoperatively might notdiovascular Surgery c Volume 146, Number 5 1149
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systemic and pulmonary resistance. Therefore, one must
be prepared to readjust the tightness of the bands. Thus,
the advantage of using Silastic slings and their anchorage
with ligaclips is the ease of adjusting them subsequently
to regulate the flow.
In the present series, all the patients who survived bPAB
had a significant reduction in the number of PCMs. The
adjustment of the Qp/Qs improves end-organ perfusion, as
reflected by the normalization of blood gases and metabolic
status. Increasing systemic blood flow could wean the
patients from inotropes, improve renal and hepatic function
and bowel and peripheral perfusion, thereby reducing
acidosis, capillary leak, and anasarca. Despite the overall
benefits from the improvement of the Qp/Qs, the direct
positive effect on systemic sepsis or primary end-organ
failure, such as liver and/or biliary dysfunction, can be
limited.
The elevated number of risk factors would possibly
contraindicate those patients for a NW1 procedure, and
the expected mortality for this group of very sick patients
would be very high. Nevertheless, we have demonstrated
that 71% of those patients who underwent the rapid
2-stage Norwood I strategy could then undergo the NW1
and, from then on, achieve outcomes comparable to those
of the low-risk HLHS group. However, a subset of patients
remains who are so sick they fail to improve after bPAB. An
alternative strategy such as extracorporeal membrane
oxygenation might need to be considered for these patients,
or they might be deemed unsalvageable.
This was a retrospective study, with all the limitations of
such a design. The decision to initiate bPAB with an aim of
undertaking a rapid 2-stage NWI was determined by the
clinical assessment of the patients in the presence of low
cardiac output, persistent acidosis, difficulty balancing the
Qp/Qs, severe hypoxemia, and cardiac arrest. We did not
use any specific algorithm or pathway to dictate when
bPAB should be used. Our aim was to demonstrate how
the result of NW1 in high-risk patients would compare
with that of standard-risk patients, when starting from a
similar baseline achieved using bPAB. We did not mean
to exaggerate the benefits of bPAB. The idea was to offer
an alternative strategy to such severely ill patients and
show that if they can undergo the Norwood, they can have
comparable survival rates. We recognize that it is important
to identify the patients who might have greater benefit from
this pathway; however, at this point, rather than increasing
the sample size, we have focused on facilitating earlier
referrals and transfer to the Norwood center.
CONCLUSIONS
The purpose of the present study was to assess the
effectiveness of a strategy to improve the clinical status of
high-risk HLHS patients such that the NW1 operation can1150 The Journal of Thoracic and Cardiovascular Surbe performed with the patient in better condition. It is
possible to reduce the number of PCMs by mechanically
optimizing the Qp/Qs, in addition to aggressive medical
support and resuscitation. The expected mortality for this
high-risk group of patients undergoing primary NW1
would be extremely high. Among the patients who survived
bPAB to undergo interval NW1, the 1-year survival was not
statistically worse than that of the standard-risk HLHS
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DDiscussion
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
Any innovation typically goes through 3 phases: a boom phase,
a bit of a disillusionment phase, and then back to a niche phase.
The hybrid procedure is no exception.
In the boom phase, it seems like the greatest innovation in the
world and widely applicable. Then, a disillusionment phase occurs
as the limitations of the innovation became apparent. Finally, it
generally finds its place in the niche phase.
At the Hospital for Sick Children, we right now have 4
indications for using the hybrid procedure: (1) as an alternative
to the Norwood; (2) pretransplant palliation in patients already
listed for transplantation; (3) to delay single ventricle, 2-ventricle
decision-making; and (4) as the ‘‘salvage procedure’’ in the group
of patients unfit for a Norwood procedure. That is the group you
have tackled, and you have tackled it well.
In our version of the salvage procedure, however, we typically
will control the patient’s pulmonary blood flow with the bands and
place a ductal stent. If the patient survives, the patient will
subsequently undergo a comprehensive stage 2 procedure. In
your paradigm, you have interposed a Norwood procedure
between attaining stability and your second stage procedure.
So I guess the most obvious question is: if you have achieved a
period of stability, you have succeeded in neutralizing these
preoperative comorbidities. Why not just stent the duct and allow
the patient to return for a comprehensive stage 2 rather than
interposing a new hazard phase associated with a Norwood
procedure, which would necessarily include all the potential
hemodynamic instability that accompanies having a balanced
circulation after a large operation?
Dr Gomide. Thank you for your comments. We think that the
hybrid procedure, as mentioned, and has been shown by some of
your studies, might not offer appropriate oxygen delivery and
that the Norwood procedure would offer better physiologic
conditions for patients in terms of antegrade flow and oxygen
delivery.
We also fear that a metal stent might provoke coarctation at the
point of the ductus arteriosus and interfere in the backflow to the
aorta. Thus, we decided to avoid the stent. This is the basic itemThe Journal of Thoracic and Carwe wanted to avoid. Also, because the patient was in a better
condition, we wanted to offer the NW1 procedure because of
these factors. Finally, because we have had satisfactory results
with the NW1, we thought that patients in better condition would
have a better prognosis with the NW1 than they would have with a
stent.
Dr Caldarone. Well, fair enough. I think the hemodynamic
studies you refer to really showed that alteration of hemodynamics
is mostly due to afterloading, acutely afterloading the neonatal
ventricle. Once you are beyond a few days, you have probably
passed that hazard phase. Anyway, it is worth ongoing discussion
about which strategy might be superior.
The other point I noticed in your report was that the preopera-
tive morbidities were grouped together, and you basically counted
them in a scoring system to identify the patients appropriate for the
salvage-type procedure. I like that method, but it does suggest that
each 1 of these preoperative comorbidities would have an
equivalent effect. I was wondering if, in your analysis, did you
try to analyze which of the preoperative comorbidities were
most important in terms of predicting a poor outcome?
Dr Gomide. No. This is one point we wanted to address.
Actually, we could have used a comprehensive score, but this study
is not about scoring the patients. We just wanted to keep it simple
and to address the number of comorbidities that are easily checked
in each patient and show that the patient at high risk can be moved
to a lower risk. We did not address the importance of each different
risk in terms of the importance for the outcome. Actually, we just
wanted to keep it simple and to send the following message: if we
have a patient with a high risk, and we reduce this patient’s risk, the
patient can have the same outcome as a patient with a conventional
risk for the Norwood.
Dr Caldarone. Going forward, will you use some more clearly
defined paradigm? In other words, if a patient shows up and starts
to accumulate preoperative comorbidities and if they hit number 4,
will you then go to the salvage strategy or will you refine that
trigger for going to the salvage strategy in the future?
Dr Gomide. No, this is a retrospective study. Actually, we
observed that those patients had this high number of comorbidities.
Usually in our practice, what happens is that the patient arrives and
is assessed clinically. If the patient is in a condition to undergo the
Norwood procedure, the patient will receive the Norwood. As we
mentioned, the indication for the Norwood depends on the clinical
status of the patient, not by counting the number of risk factors.
Actually, it is a clinical assessment. Once the patient is stable
enough, the patient will undergo the Norwood. It is not a matter
of how many preoperative comorbidities are present. This was
checked retrospectively, and it was just a cutpoint that was set.
Dr Caldarone. I guess what I am asking is: Will the results of
this study guide your decision-making in the future?
Dr Gomide. Well, they certainly will, but not in these terms. I
think that the most important message of this study is that those
patients with high risk, independently of the number of risk
factors, can have the risk category lowered by offering bPAB,
and this is the main message. It is not necessary to count the
number of risk factors and then decide whether we are going to
perform a Norwood or bPAB.
Dr Christian Pizarro (Wilmington, Del). That was an
interesting study and a very timely communication, particularlydiovascular Surgery c Volume 146, Number 5 1151
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Dbased on the discussion we had on Sunday. It seems we are finally
reaching a point where we could learn and distill who are the best
patients to undergo the hybrid procedure and who are the ones to
undergo the Norwood.
Almost about 10 years ago by now, our group and the group in
Michigan communicated the effectiveness of pulmonary artery
banding to do exactly what you describe. Also, I think that because
we embraced that approach more broadly, we went on to treat
patients with nonmodifiable factors such as chromosomal
anomalies. Not surprisingly, when we communicated those results,
5 years ago at the meeting of the European Association for
Cardio-Thoracic Surgery, the outcome, when you looked beyond
the second stage, was no different, and it was close to 50% to
60% mortality.
I think that although you have shown that there was no
difference at 1 year, you do not have the power to make that
statement. Also, I think it is likely there will be a difference. So,
you have 80% survival compared with about 62%. Experience
has told us that, for example, there are certain conditions that
you might think you would be able to modify, such as renal
dysfunction. For instance, a patient presents in shock with
significant renal dysfunction, liver dysfunction, and whatnot,
sometimes you are able to help that patient recover normal
function, not just to make urine and lower their creatinine but to
completely resolve their dysfunction. However, some of those
patients will not.
So, some of the difference that you observe in the high-risk
group is probably related to, for example, ventilator-associated
lung disease, residual renal dysfunction, and so forth. Did you
have an opportunity to actually study that patient population, the
ones who were in the high-risk group and had lower survival at
1 year to determine how many of those factors that were perceived
as recoverable actually had a sequela and how that affected the
mortality?
Dr Gomide. Yes. We have had 5 deaths in the bPAB group.
Three patients died of sepsis and severe multiorgan failure, one
of a complex congenital hepatic malformation, and one died after
a Rashkind procedure, unexplainably. Thus, the 3 patients who
died of sepsis and the patient who died of congenital hepatic
dysfunction are patients that perhaps we could not offer1152 The Journal of Thoracic and Cardiovascular Surimprovement by banding the pulmonary arteries, because the
adjustment of the Qp/Qs might improve the end-organ perfusion
but might not offer an improvement to the inflammatory response
caused by sepsis. Thus, perhaps the septic patient will not have the
same improvement as the nonseptic patient, or, even some septic
patients who respond more aggressively to the infection might
not respond to the bPAB, while some others would respond. To
identify those patients, we will additional studies.
In the case of the primary end-organ failure, perhaps we do not
improve it because it is the primary failure of the organ, and
improving the perfusion might not correlate with better outcomes.
Dr Pizarro. As you accumulate more experience, I would
encourage you to actually study and determine how many of those
patients with a recoverable lesion actually had a sequela and what
the role of that was later in their life.
Dr Shunji Sano (Okayama, Japan). We have also adopted the
rapid 2-stage banding for high-risk patients, as we presented
previously. In our series, the rapid 2-stage operation occupies
almost 20% to 30% of our series. Our indication for the rapid
2-stage is slightly different from yours. Most of our indications
have been the patient with HLHS and an intact atrial septum or
restrictive atrial septal defect with high pulmonary vascular
resistance. I am sure you have similar patients in your series, but
your indication was different. What is your strategy for the patient
with an intact atrial septum or restrictive atrial septal defect or
associated with total anomalous pulmonary venous drainage. Do
you do a rapid 2-stage in these patients or just the ordinary
Norwood?
DrGomide.Well, these patients with the restrictive atrial septal
defect usually undergo the Norwood. Our strategy differs from
yours in that we are not analyzing the usual anatomically related
risk factors but the modifiable risk factors. Therefore, the patients
had the same anatomic risk factors as the usual patients. We
actually excluded the patients with restrictive atrial septal defect
from this study. However, all the other commonly known risk
factors, such as aortic atresia or total anomalous pulmonary venous
drainage, were not considered risk factors in our group, because
our results did not show different outcomes for these patients.
Thus, they were treated in terms of the clinical risk factors that
were related.gery c November 2013
